Andreas Hochhaus

6 ta ish

Russian Medical Academy of Continuous Professional Education

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

   Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

   Sharh maqola20224 iqtibos

   ABIABI:AkademIndex/2026.other.480204

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

   Michele Baccarani, Michael Deininger, Gianantonio Rosti +29

   Sharh maqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.108143

3. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

   Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian +9

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.108166

4. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

   Andreas Hochhaus, Michele Baccarani, Richard T. Silver +31

   Sharh maqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.108182

5. EZH2 in Myeloid Malignancies

   Jenny Rinke, Andrew Chase, Nicholas C.P. Cross +2

   Sharh maqola20202 iqtibos

   ABIABI:AkademIndex/2026.other.431306

6. POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial

   Jane F. Apperley, Jörge E. Cortes, Elias Jabbour +21

   MaqolaOAOchiq kirishChronic Myeloid Leukemia TreatmentsClinical Lymphoma Myeloma & Leukemia20230 iqtibos

   ABIABI:AkademIndex/2023.article.010140